204 related articles for article (PubMed ID: 12699382)
1. An ethylenamine inhibitor binds tightly to both wild type and mutant HIV-1 proteases. Structure and energy study.
Skálová T; Hasek J; Dohnálek J; Petroková H; Buchtelová E; Dusková J; Soucek M; Majer P; Uhlíková T; Konvalinka J
J Med Chem; 2003 Apr; 46(9):1636-44. PubMed ID: 12699382
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 protease mutations and inhibitor modifications monitored on a series of complexes. Structural basis for the effect of the A71V mutation on the active site.
Skalova T; Dohnalek J; Duskova J; Petrokova H; Hradílek M; Soucek M; Konvalinka J; Hasek J
J Med Chem; 2006 Sep; 49(19):5777-84. PubMed ID: 16970402
[TBL] [Abstract][Full Text] [Related]
3. On the role of the R configuration of the reaction-intermediate isostere in HIV-1 protease-inhibitor binding: X-ray structure at 2.0 A resolution.
Dusková J; Dohnálek J; Skálová T; Petroková H; Vondrácková E; Hradílek M; Konvalinka J; Soucek M; Brynda J; Fábry M; Sedlácek J; Hasek J
Acta Crystallogr D Biol Crystallogr; 2006 May; 62(Pt 5):489-97. PubMed ID: 16627941
[TBL] [Abstract][Full Text] [Related]
4. A phenylnorstatine inhibitor binding to HIV-1 protease: geometry, protonation, and subsite-pocket interactions analyzed at atomic resolution.
Brynda J; Rezacova P; Fabry M; Horejsi M; Stouracova R; Sedlacek J; Soucek M; Hradilek M; Lepsik M; Konvalinka J
J Med Chem; 2004 Apr; 47(8):2030-6. PubMed ID: 15056001
[TBL] [Abstract][Full Text] [Related]
5. Crystal structures of complexes of a peptidic inhibitor with wild-type and two mutant HIV-1 proteases.
Hong L; Treharne A; Hartsuck JA; Foundling S; Tang J
Biochemistry; 1996 Aug; 35(33):10627-33. PubMed ID: 8718851
[TBL] [Abstract][Full Text] [Related]
6. Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance.
Hou T; Yu R
J Med Chem; 2007 Mar; 50(6):1177-88. PubMed ID: 17300185
[TBL] [Abstract][Full Text] [Related]
7. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
[TBL] [Abstract][Full Text] [Related]
8. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
Vega S; Kang LW; Velazquez-Campoy A; Kiso Y; Amzel LM; Freire E
Proteins; 2004 May; 55(3):594-602. PubMed ID: 15103623
[TBL] [Abstract][Full Text] [Related]
9. Molecular dynamic and free energy studies of primary resistance mutations in HIV-1 protease-ritonavir complexes.
Aruksakunwong O; Wolschann P; Hannongbua S; Sompornpisut P
J Chem Inf Model; 2006; 46(5):2085-92. PubMed ID: 16995739
[TBL] [Abstract][Full Text] [Related]
10. Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease.
Martin JL; Begun J; Schindeler A; Wickramasinghe WA; Alewood D; Alewood PF; Bergman DA; Brinkworth RI; Abbenante G; March DR; Reid RC; Fairlie DP
Biochemistry; 1999 Jun; 38(25):7978-88. PubMed ID: 10387041
[TBL] [Abstract][Full Text] [Related]
11. Efficiency of a second-generation HIV-1 protease inhibitor studied by molecular dynamics and absolute binding free energy calculations.
Lepsík M; Kríz Z; Havlas Z
Proteins; 2004 Nov; 57(2):279-93. PubMed ID: 15340915
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the structure of HIV-1 protease complexed with a hexapeptide inhibitor. Part II: Molecular dynamic studies of the active site region.
Geller M; Miller M; Swanson SM; Maizel J
Proteins; 1997 Feb; 27(2):195-203. PubMed ID: 9061783
[TBL] [Abstract][Full Text] [Related]
13. Molecular dynamics and free energy studies on the wild-type and mutated HIV-1 protease complexed with four approved drugs: mechanism of binding and drug resistance.
Alcaro S; Artese A; Ceccherini-Silberstein F; Ortuso F; Perno CF; Sing T; Svicher V
J Chem Inf Model; 2009 Jul; 49(7):1751-61. PubMed ID: 19537723
[TBL] [Abstract][Full Text] [Related]
14. Role of hydroxyl group and R/S configuration of isostere in binding properties of HIV-1 protease inhibitors.
Petroková H; Dusková J; Dohnálek J; Skálová T; Vondrácková-Buchtelová E; Soucek M; Konvalinka J; Brynda J; Fábry M; Sedlácek J; Hasek J
Eur J Biochem; 2004 Nov; 271(22):4451-61. PubMed ID: 15560786
[TBL] [Abstract][Full Text] [Related]
15. Some insights into mechanism for binding and drug resistance of wild type and I50V V82A and I84V mutations in HIV-1 protease with GRL-98065 inhibitor from molecular dynamic simulations.
Hu GD; Zhu T; Zhang SL; Wang D; Zhang QG
Eur J Med Chem; 2010 Jan; 45(1):227-35. PubMed ID: 19910081
[TBL] [Abstract][Full Text] [Related]
16. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
Jadhav PK; Ala P; Woerner FJ; Chang CH; Garber SS; Anton ED; Bacheler LT
J Med Chem; 1997 Jan; 40(2):181-91. PubMed ID: 9003516
[TBL] [Abstract][Full Text] [Related]
17. Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor.
Bäckbro K; Löwgren S; Osterlund K; Atepo J; Unge T; Hultén J; Bonham NM; Schaal W; Karlén A; Hallberg A
J Med Chem; 1997 Mar; 40(6):898-902. PubMed ID: 9083478
[TBL] [Abstract][Full Text] [Related]
18. Counteracting HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with XV638 and SD146, cyclic urea amides with broad specificities.
Ala PJ; Huston EE; Klabe RM; Jadhav PK; Lam PY; Chang CH
Biochemistry; 1998 Oct; 37(43):15042-9. PubMed ID: 9790666
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors.
Smith AB; Cantin LD; Pasternak A; Guise-Zawacki L; Yao W; Charnley AK; Barbosa J; Sprengeler PA; Hirschmann R; Munshi S; Olsen DB; Schleif WA; Kuo LC
J Med Chem; 2003 May; 46(10):1831-44. PubMed ID: 12723947
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of chemically synthesized HIV-1 protease and a ketomethylene isostere inhibitor based on the p2/NC cleavage site.
Torbeev VY; Mandal K; Terechko VA; Kent SB
Bioorg Med Chem Lett; 2008 Aug; 18(16):4554-7. PubMed ID: 18657969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
